Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Regulatory Effect of PD1/PD-Ligand 1 (PD-L1) on Treg Cells in Patients with Idiopathic Pulmonary Fibrosis
Bing Wang, Wenmei Bai, Hongxia Ma, et al.
Medical Science Monitor (2020) Vol. 26
Open Access | Times Cited: 20

Showing 20 citing articles:

PD-1 and PD-L1: architects of immune symphony and immunotherapy breakthroughs in cancer treatment
Adil Parvez, Furqan Choudhary, Priyal Mudgal, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 71
Soluble Programmed Death Ligand-1 (sPD-L1): A Pool of Circulating Proteins Implicated in Health and Diseases
Christian Bailly, Xavier Thuru, Bruno Quesnel
Cancers (2021) Vol. 13, Iss. 12, pp. 3034-3034
Open Access | Times Cited: 97
T cells in idiopathic pulmonary fibrosis: crucial but controversial
Lishan Deng, Teng Huang, Lei Zhang
Cell Death Discovery (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 40
The therapeutic potential of PD-1/PD-L1 pathway on immune-related diseases: Based on the innate and adaptive immune components
Peng Zhang, Yuting Wang, Qianru Miao, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 167, pp. 115569-115569
Open Access | Times Cited: 24
Emerging role of immune cells as drivers of pulmonary fibrosis
Steven E. Mutsaers, Tylah Miles, Cecilia M. Prêle, et al.
Pharmacology & Therapeutics (2023) Vol. 252, pp. 108562-108562
Closed Access | Times Cited: 23
Inhibitor of PD-1/PD-L1: a new approach may be beneficial for the treatment of idiopathic pulmonary fibrosis
Jie Tan, Qianfei Xue, Xiao Hu, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 7
PD-L1 upregulation promotes drug-induced pulmonary fibrosis by inhibiting vimentin degradation
Qing Li, Mengsheng Deng, Rentao Wang, et al.
Pharmacological Research (2022) Vol. 187, pp. 106636-106636
Open Access | Times Cited: 21
Integrated analysis reveals crosstalk between pyroptosis and immune regulation in renal fibrosis
Fengxia Bai, Longchao Han, Jifeng Yang, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 3
Single-cell transcriptomics reveals CD8+ T cell structure and developmental trajectories in idiopathic pulmonary fibrosis
Xuemei Wei, Chengji Jin, Dewei Li, et al.
Molecular Immunology (2024) Vol. 172, pp. 85-95
Open Access | Times Cited: 3
Multimorbidity In Adult Patients with Interstitial Lung Disease: An In-Patient Population-Based Observational Study
Haishuang Sun, Hongyi Wang, Yanhong Ren, et al.
(2025)
Closed Access
CD4+T and CD8+T cells profile in lung inflammation and fibrosis: targets and potential therapeutic drugs
Xiaobo Sun, Xinwen Zhang, Yejun He, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
The role of PD-1/PD-L1 axis in idiopathic pulmonary fibrosis: Friend or foe?
Aimin Jiang, Na Liu, Jingjing Wang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 16
What role does PDL1 play in EMT changes in tumors and fibrosis?
Yun-Chao Zhang, Yuting Zhang, Yi Wang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 6
Regulatory T cells in lung disease and transplantation
Peizhen Lao, Jingyi Chen, Long‐Qian Tang, et al.
Bioscience Reports (2023) Vol. 43, Iss. 10
Open Access | Times Cited: 5
Immune Stroma in Lung Cancer and Idiopathic Pulmonary Fibrosis: A Common Biologic Landscape?
Sara Lettieri, Tiberio Oggionni, Andrea Lancia, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 6, pp. 2882-2882
Open Access | Times Cited: 10
Updates on the controversial roles of regulatory lymphoid cells in idiopathic pulmonary fibrosis
Anna V Curioni, Raphaël Borie, Bruno Crestani, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 1
The Role of Resveratrol in Cancer Management: From Monotherapy to Combination Regimens
Eduarda Ribeiro, Nuno Vale
Targets (2024) Vol. 2, Iss. 4, pp. 307-326
Open Access | Times Cited: 1
Transcriptome Classification Reveals Molecular Subgroups in Idiopathic Pulmonary Fibrosis
Yuxia Liu, Chang Xu, Wenxin Gao, et al.
Genetics Research (2022) Vol. 2022, pp. 1-8
Open Access | Times Cited: 4
Evaluation of PD-1 T lymphocytes in bronchoalveolar lavage in lung cancer compared to benign lung diseases
Barbara Hammer, Chandrasekhar Bal, Maximilian Robert Gysan, et al.
Clinical and Experimental Medicine (2023) Vol. 23, Iss. 8, pp. 5177-5182
Open Access | Times Cited: 2
Spatiotemporal orchestration of a ferroptosis-immunotherapy “cycle” via a sequential drug delivery system for antitumor immunity
Yongjuan Li, Xinyan Li, Mengzhe Zhang, et al.
Nano Today (2024) Vol. 59, pp. 102535-102535
Closed Access
Effect of tacrolimus on soluble costimulatory molecules in patients with refractory myasthenia gravis
Hui Wu, Lan Chen, Xiaoling Zhou, et al.
Journal of Neuroimmunology (2022) Vol. 372, pp. 577955-577955
Closed Access | Times Cited: 1
Page 1

Scroll to top